Alessio Aligi Cogoni

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients

Matteo Lambertini, Luca Boni, Andrea Michelotti et al. · JNCI Journal of the National Cancer Institute · 2021 · 44 citations · Full text

Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system

Silvia Riva, Laura Arenare, Massimo Di Maïo et al. · BMJ Open · 2021 · 38 citations · Full text

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study

Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni et al. · The Oncologist · 2021 · 24 citations · Full text

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni et al. · BMC Cancer · 2022 · 13 citations · Full text